A beginner-friendly overview of cyclic peptides, the circular polypeptide chains that resist digestion and serve as antibiotics, immunosuppressants, and hormone analogs. This resource explains the major structural classes, including homodetic peptides, cyclic isopeptides, depsipeptides, bicyclic…
A cyclic peptide is a polypeptide chain arranged as a closed ring. Where linear peptides have a distinct amino group at one end and a carboxyl group at the other, cyclic peptides do not necessarily have free terminal ends. The circular arrangement arises through several types of covalent connections. The most common is a normal peptide bond between the amino and carboxyl ends. However, the ring can also form between an amino end and a side chain, between a carboxyl end and a side chain, or between two side chains. These options create enormous structural variety.
Cyclic peptides are produced by plants, bacteria, fungi, and marine organisms. They often serve as antibiotics, toxins, or signaling molecules. Because their circular structure protects them from enzymatic breakdown, they have become compelling candidates for oral drug development and are used in many approved medicines.
Cyclic peptides are grouped according to the chemical bonds that hold the ring together. The classification is useful because bond type influences stability, biological activity, and how the molecule is made.
Homodetic cyclic peptides contain exclusively normal peptide bonds. In these molecules, the ring is formed entirely by standard amide linkages between amino acid residues. Many naturally occurring and synthetic cyclic peptides belong to this group, and they represent the simplest form of backbone cyclization.
Cyclic isopeptides contain at least one non-alpha amide linkage. Instead of connecting the alpha carboxyl group of one residue to the alpha amino group of the next, an isopeptide bond involves side-chain amino or carboxyl groups. Microcystin, a toxin produced by cyanobacteria, and bacitracin, a polypeptide antibiotic, are representative examples of this class.
Cyclic depsipeptides incorporate one or more lactone linkages in addition to their amide bonds. A lactone is an ester formed between a carboxyl group and a hydroxyl group. Aureobasidin A, an antifungal agent produced by the fungus Aureobasidium pullulans, is a well-known cyclic depsipeptide.
Bicyclic peptides contain a second ring created by a bridging group between side chains. Amanitins, the lethal toxins found in death cap mushrooms, are bicyclic octapeptides. Their rigid, two-ring structure contributes to their potent ability to inhibit RNA polymerase and disrupt protein synthesis in cells.
Some cyclic peptides are held in a circular form by disulfide bonds between cysteine residues. Oxytocin, a nine-amino-acid hormone and medication, is cyclized through a disulfide bridge between two cysteine residues. This type of cyclization stabilizes a folded shape even though the peptide backbone itself is not closed.
Cyclotides are plant-derived peptides that are exceptionally rich in cysteine. They contain six conserved cysteine residues that form three disulfide bonds. These three interlocking disulfide bonds, combined with a cyclic backbone, create a structure called a cyclic cystine knot. The knot gives cyclotides remarkable stability against heat, chemicals, and enzymatic degradation.
Cyclic peptides are built through different biosynthetic routes depending on the organism. In plants, the process typically begins with translation of messenger RNA into a linear peptide chain. This linear precursor is then enzymatically cyclized to produce the final circular structure.
Gene-coded cyclotides are a specific example of this pathway. They are derived from precursor proteins that contain an endoplasmic reticulum signal sequence. This signal directs the precursor into the secretory pathway, where processing and cyclization can occur. Many bacterial cyclic peptides, by contrast, are assembled by non-ribosomal peptide synthetases, large multi-enzyme complexes that do not rely on an RNA template. This non-ribosomal route allows bacteria to build structurally complex rings containing amino acid variants not found in conventional proteins.
The most important property of cyclic peptides for drug development is their resistance to digestion. Because they lack free terminal ends, they are poor substrates for exopeptidases, the enzymes that normally degrade linear peptides from their ends. Endopeptidases may still cut internal bonds, but the constrained ring often limits access to cleavage sites. As a result, cyclic peptides tend to have longer half-lives in biological fluids and are being investigated as oral drug candidates.
The rigid circular structure can also improve binding to protein targets. By reducing the entropic cost of folding, the preorganized ring can bind more efficiently to its target. This makes cyclic peptides valuable scaffolds for inhibiting protein-protein interactions, a goal that is difficult to achieve with small molecule drugs.
Several clinically important drugs are cyclic peptides or closely related cyclic structures.
Bacitracin is a cyclic polypeptide antibiotic used mainly in topical preparations. It inhibits bacterial cell wall synthesis by interfering with the recycling of the lipid carrier involved in peptidoglycan assembly.
Ciclosporin is a cyclic undecapeptide with powerful immunosuppressive activity. It binds to cyclophilin inside cells, and this complex inhibits the enzyme calcineurin. By blocking calcineurin, ciclosporin prevents activation of T cells, making it essential in organ transplantation and useful in certain autoimmune diseases.
Daptomycin is a cyclic lipopeptide antibiotic that disrupts bacterial cell membranes in a calcium-dependent manner. It inserts into the membrane, causing depolarization and cell death. It is given intravenously for serious Gram-positive infections, including those caused by resistant strains.
Vancomycin is a cyclic glycopeptide antibiotic used against Gram-positive bacteria. It binds to D-alanyl-D-alanine residues in peptidoglycan precursors, blocking cell wall cross-linking. It is often reserved for severe infections such as methicillin-resistant Staphylococcus aureus.
Nisin is a cyclic antimicrobial peptide produced by lactic acid bacteria. It is classified as a lantibiotic because it contains the unusual amino acid lanthionine. Nisin has a dual mechanism: it inhibits cell wall synthesis and it forms pores in bacterial membranes. It is widely used as a food preservative.
Octreotide is a synthetic cyclic octapeptide that mimics the natural hormone somatostatin. It binds to somatostatin receptors and suppresses the release of growth hormone and other peptides. It is used clinically to treat acromegaly, certain neuroendocrine tumors, and severe diarrhea.
Polymyxin B is a cyclic lipopeptide antibiotic with activity against Gram-negative bacteria. It binds to the lipid A component of lipopolysaccharide in the outer membrane, disrupting membrane integrity. Because resistance to polymyxins is still relatively uncommon, polymyxin B is a last-resort treatment for multidrug-resistant infections caused by organisms such as Acinetobacter baumannii and Pseudomonas aeruginosa.
Some cyclic peptides described here are approved drugs in many countries, while others are research tools or toxins. Bacitracin, vancomycin, daptomycin, polymyxin B, ciclosporin, and octreotide have established medical uses. Nisin is approved as a food preservative in many regions. Amanitins are highly toxic and have no accepted therapeutic use. Cyclotides are mostly investigational at this time.
Because cyclic peptides are often large and structurally complex, their production and quality control require careful attention. The choice of a particular cyclic peptide in clinical practice depends on the indication, the route of administration, and the individual patient's condition. As with all medicines, approved prescribing information should be followed.